Saturday December 16th 2017

[Comment] Daclizumab in multiple sclerosis: a high-yield extension study

Monoclonal antibodies have emerged as effective treatments for patients with multiple sclerosis. They bind to specific proteins on the surface of the immune cells that are involved in the cascade of events leading to pathological changes associated with the disease: rituximab, ocrelizumab, and ofatumumab target CD20 (also known as MS4A1), which is present on only B cells; alemtuzumab binds to CD52 on the surface of many types of white cells; and natalizumab binds to the alpha-4 integrin (ITGA4) on the surface of lymphocytes, thereby reducing the movement of these cells across the vascular endothelium. (Source: Lancet Neurology)

Read this article: 

[Comment] Daclizumab in multiple sclerosis: a high-yield extension study

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]